Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526450 | 0.82 | EPHX2 (0.53) | EPHX2EPHX1LMNANPSR1ALDH1A1 | |
| SCHEMBL3213643 | 0.80 | EPHX2 (1.00) | EPHX2EPHX1LMNA | |
| SCHEMBL3930414 | 0.78 | EPHX2 (0.63) | EPHX2LMNATP53NPSR1MAPT | |
| SCHEMBL8048274 | 0.77 | EPHX1 (0.69) | EPHX2EPHX1LMNA | |
| SCHEMBL3928608 | 0.76 | EPHX2 (0.61) | EPHX2LMNATP53NPSR1ALDH1A1 | |
| SCHEMBL3918142 | 0.76 | ALOX15 (0.52) | EPHX2EPHX1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL2638872 | 0.76 | EPHX2 (0.57) | EPHX2EPHX1ALDH1A1MEN1KMT2A | |
| SCHEMBL15313029 | 0.75 | EPHX2 (0.72) | EPHX2EPHX1LMNA | |
| SCHEMBL3920881 | 0.75 | POLB (0.64) | EPHX2LMNATP53ALDH1A1POLB | |
| SCHEMBL3928458 | 0.75 | MEN1 (0.58) | EPHX2LMNATP53MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | claimed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HSD11B1, HSD3B1, CES1 | EPHX2 2010/4885EPHX1 716/4885LMNA 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.